Clinical Updates in Treating Advanced Prostate Cancer - Episode 9

ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

,

Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.

What are your thoughts on the CONTACT-02 trial?